The hepatitis B treatment does not pursue and make short work of It is most important to reduce hepatocarcinoma

The hepatitis B treatment does not pursue and make short work of It is most important to reduce hepatocarcinoma
In the near future, all parts will cancel to workers and enter hepatitis B that the duty, student entered school and measure the project one after another, and exactly the third on May 19 " The day of hepatitis of world " ,The statistics show, nearly there are 20 million chronic hepatitis B patients at present in our country. The Temple of Earth hospital Vice President establishes an army a professor points out, treat time and medicine and able to bear questions such as medicines,etc. as to hepatitis B, the patient needs to go out of some mistaken ideas, establish correct understanding. The hepatitis B treatment is not pursued " Make short work of " At present, all guides treat the goal and delay and prevent disease progress to chronic hepatitis B, reduce and prevent the liver from losing compensating, emergence of liver cirrhosis, hepatocarcinoma and complication, but a lot of patients will be misled in the course of treating. A professor points out, in order to realize treating the goal, should observe the basic policy of the treatment of chronic hepatitis B to establish an army, namely a centre, four basic points. A centre, regard antiviral treatment for a long time as the centre; Four basic points, insist there are few liver cirrhosis, hepatocarcinoma in selecting medicine, adhere to few side effects, insist on the expenses little, insist on treating optimally. The majority of hepatitis B patients hope and can cure and park medicines in short term, but no matter interferon or nucleoside is (sour) The analog is short-term ' No more than one year) After medicines stopped in the treatment, patient's condition will all rebound, it means the chronic hepatitis B treatment is a protracted war. " prevent and cure guide " against virus suggestion to take orally " by chronic hepatitis B: Three big open patients treat for 24 months at least, three small open patient therapeutic time need longer, there is no clear stopping the medicine index at present. Half a year monitor and is able to bear the medicine key A lot of people to " Able to bear medicines " The color smelt changes, but the expert points out, all nucleoside (acid) The analogs may all be able to bear medicines, being able to bear medicines can defend treating, not terrible. A professor introduces to establish an army, it has a course too that hepatitis B is able to bear medicines, before taking place and is able to bear medicines clinically, many kinds of clues and indexes appear. The hepatitis B patient, through insisting on following up a case by regular visits to, intervene and not merely can prevent and manage and able to bear medicines effectively as soon as possible, also can obtain satisfactory curative effect, and 24 weeks (half a year) Treat the key time point. For example whether it use on Lammi,at this moment lower than copying 1* 103 hepatitis B virus level /ml, continue single medicine treatment; It if higher than 1* 103 it copy /ml,need to add by medicine in time, being it is superior to changing dressings not to last medicine and be can increase not merely by therapeutic effect soeded, probability happens to can reduce greatly and is able to bear medicine. In addition, though four major nucleoside (acid) One kind of medicines has all already entered the national medical insurance catalogue, but for most hepatitis B patients, the proportion of submitting an expense account is correlated with price of the medicine. So the patient calculates carefully and budgets strictly while selecting medicine, choose to insist on the therapeutic medicine from 2 to 3 at least oneself. Reducing the most important duplication because of hepatitis B and virus of liver cirrhosis, hepatocarcinoma is not inhibited effectively, a lot of patients' condition worsen for liver cirrhosis, hepatocarcinoma, and pay the life for this. Establish an army to point out, if hepatitis B and virus are duplicated and can't be inhibited effectively, 5 years later, about 10%- 20% of the chronic hepatitis B patients can develop into liver cirrhosis, 15% of the liver cirrhosis among them can develop into and lose, compensate a liver cirrhosis, 5%- 20% liver cirrhosis can develop into the intersection of liver and cellulous hepatocarcinoma, reduce liver cirrhosis, hepatocarcinoma, we can say it is a final purpose. And announce newly " 4006 is studied " To follow up a case by regular visits to result find, have after the intersection of liver cirrhosis and patient treat for a long time definitely by Lammi some early period 10 year, most HBV-DNA turn overcast, 75% of the patients have reached histologic improvement, has delayed the progress of disease. The result verified, the made the antiviral treatment for 3 years through Lammi this 4006 research 3s announced in the past 2004 years, can make the risk of disease progress reduce by 55%, the risk that hepatocarcinoma takes place is reduced by 51%. 4006 it studies to be the intersection of hepatitis B and field have milestone only meaning, global many centre prospective to study, altogether of Lammi with the participation of 641 patients, 41 countries in the world fixes the antiviral treatment to study.

|